ALISO VIEJO, Calif., March 31 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International today announced the appointment of Steve Stefano to its Board of Directors. Mr. Stefano was appointed to fill a vacant board position with a term that expires at the 2010 Annual Stockholders Meeting. Mr. Stefano's election brings the company's board to nine members.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)
"We are pleased to add someone of Steve's caliber to our Board," said J. Michael Pearson, Chairman and Chief Executive Officer. "Given his experience in the managed care area, coupled with his leadership and experience at our partner GlaxoSmithKline, Steve will provide valuable insight and perspective to our already diverse Board."
Mr. Stefano is Senior Vice President of GlaxoSmithKline's Payor Markets Division and has spent twenty-three years leading GlaxoSmithKline's Managed Markets Division. Mr. Stefano has held numerous positions at the previous Glaxo Wellcome, inclusive of leading all of the company's Primary Care Sales Force as well as heading up each of the Specialty Divisions (Oncology, HIV and NeuroHealth). He is credited with building the company's strategy in Managed Care.
About Valeant
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.
CONTACT: Laurie W. Little of Valeant Pharmaceuticals International,
+1-949-461-6002
Web site: http://www.valeant.com/
